Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
McKesson
Daiichi Sankyo
Teva
Covington
Baxter
Chubb
Chinese Patent Office
Healthtrust

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,618,141

« Back to Dashboard

Which drugs does patent 8,618,141 protect, and when does it expire?

Patent 8,618,141 protects NEXAVAR and is included in one NDA.

This patent has twelve patent family members in eleven countries.
Summary for Patent: 8,618,141
Title:Aryl ureas with angiogenesis inhibiting activity
Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Inventor(s): Dumas; Jacques (Bethany, CT), Scott; William J. (Guilford, CT), Elting; James (Madison, CT), Hatoum-Makdad; Holia (Hamden, CT)
Assignee: Bayer Healthcare LLC (Whippany, NJ)
Application Number:13/551,884
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,618,141
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,618,141

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ADVANCED RENAL CELL CARCINOMA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,618,141

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,838,541 Aryl ureas with angiogenesis inhibiting activity ➤ Try a Free Trial
8,242,147 Aryl ureas with angiogenisis inhibiting activity ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,618,141

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2475703 ➤ Try a Free Trial
Denmark 1478358 ➤ Try a Free Trial
European Patent Office 1478358 ➤ Try a Free Trial
European Patent Office 2324825 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
US Department of Justice
Chinese Patent Office
QuintilesIMS
Fuji
Moodys
Medtronic
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.